-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Presents Data From Investigator-Initiated Phase II Trial, Evaluating agenT-797, MiNK's allo-iNKT Cell Therapy, In Combination With BOT And BAL, Ramucirumab And Paclitaxel In PD-1 Refractory Gastroesophageal Cancer, At 2026 AACR Annual Meeting

Benzinga·04/17/2026 19:03:26
Listen to the news
  • First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patients
  • Induction strategy linked to improvement in PFS (HR 0.19; p=0,015) and survival rates at 12 and 18 months supported by evidence of immune activation and tumor immune reprogramming

     

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, evaluating agenT-797, MiNK's allo-iNKT cell therapy, in combination with botensilimab (BOT) and balstilimab (BAL), ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA.